{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:06:59Z","timestamp":1791979619655,"version":"4.4.0"},"reference-count":234,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10096-021-04296-1","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T21:02:26Z","timestamp":1624568546000},"page":"2053-2068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-4327","authenticated-orcid":false,"given":"Kathleen","family":"Tompkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"4296_CR1","unstructured":"The World Health Organization . Antibiotic resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antibiotic-resistance. Accessed 25 Feb 2021"},{"key":"4296_CR2","unstructured":"United States Centers for Disease Control and Prevention. Clinicians: Information about CRE. https:\/\/www.cdc.gov\/hai\/organisms\/cre\/cre-clinicians.html (2019). Accessed 25 Feb 2021"},{"key":"4296_CR3","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (2011) Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943\u20134960","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","volume":"8","author":"D van Duin","year":"2017","unstructured":"van Duin D, Doi Y (2017) The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8:460\u2013469","journal-title":"Virulence"},{"key":"4296_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/1469-0691.12719","volume":"20","author":"P Nordmann","year":"2014","unstructured":"Nordmann P, Poirel L (2014) The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821\u2013830","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","volume":"17","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791\u20131798","journal-title":"Emerg Infect Dis"},{"key":"4296_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/cix893","volume":"66","author":"RA Bonomo","year":"2018","unstructured":"Bonomo RA et al (2018) Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis 66:1290\u20131297","journal-title":"Clin Infect Dis"},{"key":"4296_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijantimicag.2017.03.012","volume":"50","author":"AM Kelly","year":"2017","unstructured":"Kelly AM, Mathema B, Larson EL (2017) Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents 50:127\u2013134","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/antibiotics10010061","volume":"10","author":"P Barbadoro","year":"2021","unstructured":"Barbadoro P et al (2021) Carriage of Carbapenem-Resistant Enterobacterales in Adult Patients Admitted to a University Hospital in Italy. Antibiotics (Basel) 10:61","journal-title":"Antibiotics (Basel)"},{"key":"4296_CR10","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.2147\/IDR.S260804","volume":"13","author":"H Hu","year":"2020","unstructured":"Hu H et al (2020) Clinical and microbiological characteristics of community-onset Carbapenem-resistant Enterobacteriaceae isolates. Infect Drug Resist 13:3131\u20133143","journal-title":"Infect Drug Resist"},{"key":"4296_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.idc.2020.08.002","volume":"34","author":"D van Duin","year":"2020","unstructured":"van Duin D, Paterson DL (2020) Multidrug-resistant bacteria in the community: an update. Infect Dis Clin North Am 34:709\u2013722","journal-title":"Infect Dis Clin North Am"},{"key":"4296_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/antibiotics9100693","volume":"9","author":"G Taggar","year":"2020","unstructured":"Taggar G, Attiq Rheman M, Boerlin P, Diarra MS (2020) Molecular Epidemiology of Carbapenemases in Enterobacteriales from Humans, Animals Food and the Environment. Antibiotics (Basel) 9:693","journal-title":"Antibiotics (Basel)"},{"key":"4296_CR13","doi-asserted-by":"publisher","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","volume":"5","author":"A Martin","year":"2018","unstructured":"Martin A, Fahrbach K, Zhao Q, Lodise T (2018) Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis. Open Forum Infect Dis 5:ofy150","journal-title":"Open Forum Infect Dis"},{"key":"4296_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1017\/ice.2017.197","volume":"38","author":"PP Kohler","year":"2017","unstructured":"Kohler PP et al (2017) Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 38:1319\u20131328","journal-title":"Infect Control Hosp Epidemiol"},{"key":"4296_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","volume":"17","author":"MD Zilberberg","year":"2017","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF (2017) Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 17:279","journal-title":"BMC Infect Dis"},{"issue":"48","key":"4296_CR16","first-page":"e9","volume":"23","author":"SM Bartsch","year":"2017","unstructured":"Bartsch SM et al (2017) Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 23(48):e9-48.e16","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajic.2019.07.006","volume":"48","author":"O Igbinosa","year":"2020","unstructured":"Igbinosa O, Dogho P, Osadiaye N (2020) Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital. Am J Infect Control 48:7\u201312","journal-title":"Am J Infect Control"},{"key":"4296_CR18","doi-asserted-by":"publisher","first-page":"616793","DOI":"10.3389\/fpubh.2021.616793","volume":"9","author":"A Adar","year":"2021","unstructured":"Adar A et al (2021) Clinical and Demographic Characteristics of Patients With a New Diagnosis of Carriage or Clinical Infection With Carbapenemase-Producing Enterobacterales: A Retrospective Study. Front Public Health 9:616793","journal-title":"Front Public Health"},{"key":"4296_CR19","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1128\/AAC.01758-13","volume":"58","author":"AF Voor In\u2019t Holt","year":"2014","unstructured":"Voor In\u2019t Holt AF, Severin JA, Lesaffre EMEH, Vos MC (2014) A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:2626\u20132637","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR20","doi-asserted-by":"publisher","unstructured":"Tamma PD et al (2020) Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis doi:https:\/\/doi.org\/10.1093\/cid\/ciaa1478","DOI":"10.1093\/cid\/ciaa1478"},{"key":"4296_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13613-015-0061-0","volume":"5","author":"\u00c9 Rupp\u00e9","year":"2015","unstructured":"Rupp\u00e9 \u00c9, Woerther P-L, Barbier F (2015) Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 5:61","journal-title":"Ann Intensive Care"},{"key":"4296_CR22","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann P, Poirel L (2019) Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis 69:S521\u2013S528","journal-title":"Clin Infect Dis"},{"key":"4296_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","volume":"20","author":"AM Queenan","year":"2007","unstructured":"Queenan AM, Bush K (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440\u201358 (table of contents)","journal-title":"Clin Microbiol Rev"},{"key":"4296_CR24","first-page":"e00047","volume":"33","author":"K Bush","year":"2020","unstructured":"Bush K, Bradford PA (2020) Epidemiology of \u03b2-Lactamase-Producing Pathogens. Clin Microbio Rev 33:e00047-19","journal-title":"Clin Microbio Rev"},{"key":"4296_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02000-20","author":"KM Kazmierczak","year":"2021","unstructured":"Kazmierczak KM, Karlowsky JA, de Jonge BLM, Stone GG, Sahm DF (2021) Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-nonsusceptible Enterobacterales collected as part of a Global Surveillance Program, 2012\u20132017. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02000-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","volume":"20","author":"D van Duin","year":"2020","unstructured":"van Duin D et al (2020) Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis 20:731\u2013741","journal-title":"Lancet Infect Dis"},{"key":"4296_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1469-0691.2002.00401.x","volume":"8","author":"P Nordmann","year":"2002","unstructured":"Nordmann P, Poirel L (2002) Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8:321\u2013331","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmolb.2018.00016","volume":"5","author":"T Palzkill","year":"2018","unstructured":"Palzkill T (2018) Structural and Mechanistic Basis for Extended-Spectrum Drug-Resistance Mutations in Altering the Specificity of TEM, CTX-M, and KPC \u03b2-lactamases. Front Mol Biosci 5:16","journal-title":"Front Mol Biosci"},{"key":"4296_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/jac\/dkm226","volume":"60","author":"J Walther-Rasmussen","year":"2007","unstructured":"Walther-Rasmussen J, H\u00f8iby N (2007) Class A carbapenemases. J Antimicrob Chemother 60:470\u2013482","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR30","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1128\/AAC.48.11.4438-4440.2004","volume":"48","author":"A Hossain","year":"2004","unstructured":"Hossain A et al (2004) Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 48:4438\u20134440","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","volume":"45","author":"H Yigit","year":"2001","unstructured":"Yigit H et al (2001) Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151\u20131161","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/mdr.2006.12.223","volume":"12","author":"LM Deshpande","year":"2006","unstructured":"Deshpande LM, Jones RN, Fritsche TR, Sader HS (2006) Occurrence and Characterization of Carbapenemase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000\u20132004). Microb Drug Resist 12:223\u2013230","journal-title":"Microb Drug Resist"},{"key":"4296_CR33","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1128\/AAC.02252-12","volume":"57","author":"M Castanheira","year":"2013","unstructured":"Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN (2013) Prevalence of \u03b2-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57:3012\u20133020","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR34","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1128\/AAC.00186-06","volume":"50","author":"MV Villegas","year":"2006","unstructured":"Villegas MV et al (2006) First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 50:2880\u20132882","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR35","doi-asserted-by":"publisher","first-page":"e01743","DOI":"10.1128\/AAC.01743-20","volume":"64","author":"AM Rada","year":"2020","unstructured":"Rada AM et al (2020) Dynamics of blaKPC-2 Dissemination from Non-CG258 Klebsiella pneumoniae to Other Enterobacterales via IncN Plasmids in an Area of High Endemicity. Antimicrob Agents Chemother 64:e01743-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR36","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00987-08","volume":"53","author":"S Navon-Venezia","year":"2009","unstructured":"Navon-Venezia S et al (2009) First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 53:818\u2013820","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2217\/fmb-2016-0042","volume":"11","author":"T Karampatakis","year":"2016","unstructured":"Karampatakis T, Antachopoulos C, Iosifidis E, Tsakris A, Roilides E (2016) Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece. Future Microbiol 11:809\u2013823","journal-title":"Future Microbiol"},{"key":"4296_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cmi.2017.12.007","volume":"24","author":"K Gartzonika","year":"2018","unstructured":"Gartzonika K et al (2018) Identification of a KPC-9-producing Klebsiella pneumoniae ST258 cluster among KPC-2-producing isolates of an ongoing outbreak in Northwestern Greece: a retrospective study. Clin Microbiol Infect 24:558\u2013560","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1017\/S0950268816002442","volume":"145","author":"D Vubil","year":"2017","unstructured":"Vubil D et al (2017) Outbreak of KPC-3-producing ST15 and ST348 Klebsiella pneumoniae in a Portuguese hospital. Epidemiol Infect 145:595\u2013599","journal-title":"Epidemiol Infect"},{"key":"4296_CR40","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/jac\/dkx054","volume":"72","author":"A Baraniak","year":"2017","unstructured":"Baraniak A et al (2017) Multiregional dissemination of KPC-producing Klebsiella pneumoniae ST258\/ST512 genotypes in Poland, 2010\u201314. J Antimicrob Chemother 72:1610\u20131616","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR41","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.jmb.2019.04.002","volume":"431","author":"CL Tooke","year":"2019","unstructured":"Tooke CL et al (2019) \u03b2-Lactamases and \u03b2-Lactamase Inhibitors in the 21st Century. J Mol Biol 431:3472\u20133500","journal-title":"J Mol Biol"},{"key":"4296_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2016.09.002","volume":"29","author":"RF Potter","year":"2016","unstructured":"Potter RF, D\u2019Souza AW, Dantas G (2016) The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat 29:30\u201346","journal-title":"Drug Resist Updat"},{"key":"4296_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1128\/CMR.18.2.306-325.2005","volume":"18","author":"TR Walsh","year":"2005","unstructured":"Walsh TR, Toleman MA, Poirel L, Nordmann P (2005) Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306\u2013325","journal-title":"Clin Microbiol Rev"},{"key":"4296_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1469-0691.2005.01264.x","volume":"11","author":"TR Walsh","year":"2005","unstructured":"Walsh TR (2005) The emergence and implications of metallo-\u03b2-lactamases in Gram-negative bacteria. Clin Microbiol Infect 11:2\u20139","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR45","doi-asserted-by":"publisher","unstructured":"Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z (2019) NDM metallo-\u03b2-lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 32. https:\/\/doi.org\/10.1128\/CMR.00115-18","DOI":"10.1128\/CMR.00115-18"},{"key":"4296_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/AAC.35.1.147","volume":"35","author":"M Watanabe","year":"1991","unstructured":"Watanabe M, Iyobe S, Inoue M, Mitsuhashi S (1991) Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35:147\u2013151","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijantimicag.2019.07.019","volume":"54","author":"MD Malchione","year":"2019","unstructured":"Malchione MD, Torres LM, Hartley DM, Koch M, Goodman JL (2019) Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges. Int J Antimicrob Agents 54:381\u2013399","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR48","first-page":"e02729","volume":"61","author":"Y Matsumura","year":"2017","unstructured":"Matsumura Y et al (2017) Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae. Antimicrob Agents Chemother 61:e02729-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR49","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.43.7.1584","volume":"43","author":"L Lauretti","year":"1999","unstructured":"Lauretti L et al (1999) Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 43:1584\u20131590","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR50","doi-asserted-by":"publisher","unstructured":"Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL (2015) European survey of carbapenemase-producing enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 20. https:\/\/doi.org\/10.2807\/1560-7917.ES.2015.20.45.30062","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062"},{"key":"4296_CR51","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/AAC.00774-09","volume":"53","author":"D Yong","year":"2009","unstructured":"Yong D et al (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046\u20135054","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10096-017-3112-7","volume":"37","author":"A Mairi","year":"2018","unstructured":"Mairi A, Pantel A, Sotto A, Lavigne J-P, Touati A (2018) OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur J Clin Microbiol Infect Dis 37:587\u2013604","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4296_CR53","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/jac\/dks121","volume":"67","author":"L Poirel","year":"2012","unstructured":"Poirel L, Potron A, Nordmann P (2012) OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597\u20131606","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR54","doi-asserted-by":"publisher","first-page":"e00102","DOI":"10.1128\/CMR.00102-19","volume":"33","author":"JDD Pitout","year":"2019","unstructured":"Pitout JDD, Peirano G, Kock MM, Strydom K-A, Matsumura Y (2019) The Global Ascendency of OXA-48-Type Carbapenemases. Clin Microbiol Rev 33:e00102-19","journal-title":"Clin Microbiol Rev"},{"key":"4296_CR55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/jac\/dki482","volume":"57","author":"J Walther-Rasmussen","year":"2006","unstructured":"Walther-Rasmussen J, H\u00f8iby N (2006) OXA-type carbapenemases. J Antimicrob Chemother 57:373\u2013383","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2012.03.003","volume":"18","author":"P Nordmann","year":"2012","unstructured":"Nordmann P, Dortet L, Poirel L (2012) Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18:263\u2013272","journal-title":"Trends Mol Med"},{"key":"4296_CR57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jgar.2021.01.008","volume":"24","author":"J Guzm\u00e1n-Puche","year":"2021","unstructured":"Guzm\u00e1n-Puche J et al (2021) Characterization of OXA-48-producing Klebsiella oxytoca isolates from a hospital outbreak in Tunisia. J Glob Antimicrob Resist 24:306\u2013310","journal-title":"J Glob Antimicrob Resist"},{"key":"4296_CR58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jhin.2020.07.017","volume":"106","author":"L Heireman","year":"2020","unstructured":"Heireman L et al (2020) Toilet drain water as a potential source of hospital room-to-room transmission of carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 106:232\u2013239","journal-title":"J Hosp Infect"},{"key":"4296_CR59","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/antibiotics9120862","volume":"9","author":"E Shaidullina","year":"2020","unstructured":"Shaidullina E et al (2020) Antimicrobial Resistance and Genomic Characterization of OXA-48- and CTX-M-15-Co-Producing Hypervirulent Klebsiella pneumoniae ST23 Recovered from Nosocomial Outbreak. Antibiotics (Basel) 9:862","journal-title":"Antibiotics (Basel)"},{"key":"4296_CR60","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.15585\/mmwr.mm6447a3","volume":"64","author":"M Lyman","year":"2015","unstructured":"Lyman M et al (2015) Notes from the Field: Carbapenem-resistant Enterobacteriaceae Producing OXA-48-like Carbapenemases-United States, 2010\u20132015. MMWR Morb Mortal Wkly Rep 64:1315\u20131316","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4296_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/fmb.14.135","volume":"10","author":"S-S Jean","year":"2015","unstructured":"Jean S-S et al (2015) Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 10:407\u2013425","journal-title":"Future Microbiol"},{"key":"4296_CR62","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1099\/jmm.0.001052","volume":"68","author":"P Ract","year":"2019","unstructured":"Ract P et al (2019) Synergistic in vitro activity between aztreonam and amoxicillin-clavulanate against Enterobacteriaceae-producing class B and\/or class D carbapenemases with or without extended-spectrum \u03b2-lactamases. J Med Microbiol 68:1292\u20131298","journal-title":"J Med Microbiol"},{"key":"4296_CR63","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1586\/eri.12.78","volume":"10","author":"S Biswas","year":"2012","unstructured":"Biswas S, Brunel J-M, Dubus J-C, Reynaud-Gaubert M, Rolain J-M (2012) Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 10:917\u2013934","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4296_CR64","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1111\/1469-0691.12070","volume":"19","author":"A Capone","year":"2013","unstructured":"Capone A et al (2013) High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 19:E23\u2013E30","journal-title":"Clin Microbiol Infect"},{"issue":"1106","key":"4296_CR65","first-page":"e1","volume":"21","author":"DR Giacobbe","year":"2015","unstructured":"Giacobbe DR et al (2015) Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 21(1106):e1-8","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR66","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10123-019-00112-1","volume":"23","author":"J Kai","year":"2020","unstructured":"Kai J, Wang S (2020) Recent progress on elucidating the molecular mechanism of plasmid-mediated colistin resistance and drug design. Int Microbiol 23:355\u2013366","journal-title":"Int Microbiol"},{"key":"4296_CR67","doi-asserted-by":"publisher","first-page":"e02881","DOI":"10.1128\/mBio.02881-20","volume":"12","author":"VI Band","year":"2021","unstructured":"Band VI et al (2021) Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States. MBio 12:e02881-20","journal-title":"MBio"},{"key":"4296_CR68","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12275-021-0610-1","volume":"59","author":"J Seo","year":"2021","unstructured":"Seo J, Wi YM, Kim JM, Kim Y-J, Ko KS (2021) Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing Klebsiella pneumoniae clinical isolates. J Microbiol 59:590\u2013597","journal-title":"J Microbiol"},{"key":"4296_CR69","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","volume":"70","author":"J Motsch","year":"2020","unstructured":"Motsch J et al (2020) RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 70:1799\u20131808","journal-title":"Clin Infect Dis"},{"key":"4296_CR70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG et al (2018) Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 7:439\u2013455","journal-title":"Infect Dis Ther"},{"key":"4296_CR71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D et al (2018) Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 66:163\u2013171","journal-title":"Clin Infect Dis"},{"key":"4296_CR72","doi-asserted-by":"publisher","first-page":"367","DOI":"10.18683\/germs.2020.1229","volume":"10","author":"A Olowo-Okere","year":"2020","unstructured":"Olowo-Okere A, Yacouba A (2020) Molecular mechanisms of colistin resistance in Africa: A systematic review of literature. Germs 10:367\u2013379","journal-title":"Germs"},{"key":"4296_CR73","doi-asserted-by":"publisher","unstructured":"Osei Sekyere J, Reta MA (2020) Genomic and resistance epidemiology of gram-negative bacteria in Africa: a Systematic review and phylogenomic analyses from a one health perspective. mSystems 5. https:\/\/doi.org\/10.1128\/mSystems.00897-20","DOI":"10.1128\/mSystems.00897-20"},{"key":"4296_CR74","unstructured":"World Health Organization (2018) The detection and reporting of colistin resistance. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/277175\/WHO-WSI-AMR-2018.4-eng.pdf. Accessed 1 Jun 2021"},{"key":"4296_CR75","unstructured":"WHO | Highest Priority Critically Important Antimicrobials (2019) World health organization.\u00a0Available: https:\/\/www.who.int\/foodsafety\/cia\/en\/. Accessed 1 Jun\u00a02021"},{"key":"4296_CR76","doi-asserted-by":"publisher","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","volume":"7","author":"LL Silver","year":"2017","unstructured":"Silver LL (2017) Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med 7:a025262","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4296_CR77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ (2016) Fosfomycin. Clin Microbiol Rev 29:321\u2013347","journal-title":"Clin Microbiol Rev"},{"key":"4296_CR78","doi-asserted-by":"publisher","first-page":"e00749","DOI":"10.1128\/mBio.00749-17","volume":"8","author":"R Ito","year":"2017","unstructured":"Ito R et al (2017) Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. MBio 8:e00749-17","journal-title":"MBio"},{"key":"4296_CR79","doi-asserted-by":"publisher","first-page":"106226","DOI":"10.1016\/j.ijantimicag.2020.106226","volume":"57","author":"L Huang","year":"2021","unstructured":"Huang L et al (2021) Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China. Int J Antimicrob Agents 57:106226","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR80","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15:e732\u2013e739","journal-title":"Int J Infect Dis"},{"key":"4296_CR81","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI (2008) Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46:1069\u20131077","journal-title":"Clin Infect Dis"},{"key":"4296_CR82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","volume":"16","author":"A Michalopoulos","year":"2010","unstructured":"Michalopoulos A et al (2010) Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 16:184\u2013186","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","volume":"43","author":"K Pontikis","year":"2014","unstructured":"Pontikis K et al (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43:52\u201359","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR84","unstructured":"US Food and Drug Administration. MONUROL. US Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050717s007lbl.pdf. Accessed 1 Jun 2021"},{"key":"4296_CR85","unstructured":"Dimitrova EK (2018) Fosfomycin-containing medicinal products. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/fosfomycin-containing-medicinal-products. Accessed 1 Jun 2021"},{"key":"4296_CR86","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ijantimicag.2018.07.003","volume":"52","author":"H Seifert","year":"2018","unstructured":"Seifert H, Blondeau J, Dowzicky MJ (2018) In vitro activity of tigecycline and comparators (2014-2016) among key WHO \u2018priority pathogens\u2019 and longitudinal assessment (2014-2016) of antimicrobial resistance: a report from the T.E.S.T. study. Int J Antimicrob Agents 52:474\u2013484","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR87","doi-asserted-by":"publisher","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","volume":"95","author":"W Ni","year":"2016","unstructured":"Ni W et al (2016) Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine 95:e3126","journal-title":"Medicine"},{"key":"4296_CR88","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/cid\/cis969","volume":"56","author":"F Sbrana","year":"2013","unstructured":"Sbrana F et al (2013) Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 56:697\u2013700","journal-title":"Clin Infect Dis"},{"key":"4296_CR89","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"importance of combination therapy","year":"2012","unstructured":"importance of combination therapy (2012) Tumbarello, M. et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 55:943\u2013950","journal-title":"Clin Infect Dis"},{"key":"4296_CR90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2016.04.017","volume":"48","author":"S Pournaras","year":"2016","unstructured":"Pournaras S, Koumaki V, Spanakis N, Gennimata V, Tsakris A (2016) Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. Int J Antimicrob Agents 48:11\u201318","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3343\/alm.2020.40.1.15","volume":"40","author":"EJ Yoon","year":"2020","unstructured":"Yoon EJ, Oh Y, Jeong SH (2020) Development of Tigecycline Resistance in Carbapenemase-Producing Klebsiella pneumoniae Sequence Type 147 via AcrAB Overproduction Mediated by Replacement of the ramA Promoter. Ann Lab Med 40:15\u201320","journal-title":"Ann Lab Med"},{"key":"4296_CR92","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41564-019-0496-4","volume":"4","author":"J Sun","year":"2019","unstructured":"Sun J et al (2019) Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat Microbiol 4:1457\u20131464","journal-title":"Nat Microbiol"},{"key":"4296_CR93","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41564-019-0445-2","volume":"4","author":"T He","year":"2019","unstructured":"He T et al (2019) Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol 4:1450\u20131456","journal-title":"Nat Microbiol"},{"key":"4296_CR94","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fcimb.2019.00193","volume":"9","author":"L Peyclit","year":"2019","unstructured":"Peyclit L, Baron SA, Rolain J-M (2019) Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria. Front Cell Infect Microbiol 9:193","journal-title":"Front Cell Infect Microbiol"},{"key":"4296_CR95","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41467-018-02875-z","volume":"9","author":"CR MacNair","year":"2018","unstructured":"MacNair CR et al (2018) Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun 9:458","journal-title":"Nat Commun"},{"key":"4296_CR96","doi-asserted-by":"publisher","unstructured":"Hu Y, Liu Y, Coates A (2019) Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant enterobacteriaceae. Antimicrob Agents Chemother 63. https:\/\/doi.org\/10.1128\/AAC.01630-18","DOI":"10.1128\/AAC.01630-18"},{"key":"4296_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10096-017-3114-5","volume":"37","author":"SMS Ng","year":"2018","unstructured":"Ng SMS et al (2018) Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. Eur J Clin Microbiol Infect Dis 37:141\u2013148","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4296_CR98","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fcimb.2018.00363","volume":"8","author":"T Cebrero-Cangueiro","year":"2018","unstructured":"Cebrero-Cangueiro T et al (2018) In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and\/or Colistin-Resistant Enterobacteriaceae. Front Cell Infect Microbiol 8:363","journal-title":"Front Cell Infect Microbiol"},{"key":"4296_CR99","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijantimicag.2018.09.003","volume":"53","author":"RG Otto","year":"2019","unstructured":"Otto RG et al (2019) An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics. Int J Antimicrob Agents 53:34\u201339","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR100","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG et al (2013) Ceftazidime-Avibactam: a Novel Cephalosporin\/b-lactamase Inhibitor Combination. Drugs; Auckland 73:159\u2013177","journal-title":"Drugs; Auckland"},{"key":"4296_CR101","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE et al (2012) Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663\u201311668","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4296_CR102","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","volume":"73","author":"A Sousa","year":"2018","unstructured":"Sousa A et al (2018) Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 73:3170\u20133175","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR103","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","volume":"53","author":"C De la Calle","year":"2019","unstructured":"De la Calle C et al (2019) Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents 53:520\u2013524","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR104","first-page":"e00883","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK et al (2017) Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother 61:e00883-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR105","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab176","author":"M Tumbarello","year":"2021","unstructured":"Tumbarello M et al (2021) Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciab176","journal-title":"Clin Infect Dis"},{"key":"4296_CR106","doi-asserted-by":"publisher","first-page":"ofaa651","DOI":"10.1093\/ofid\/ofaa651","volume":"8","author":"GM Wilson","year":"2021","unstructured":"Wilson GM et al (2021) Meta-analysis of Clinical Outcomes Using Ceftazidime\/Avibactam, Ceftolozane\/Tazobactam, and Meropenem\/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis 8:ofaa651","journal-title":"Open Forum Infect Dis"},{"key":"4296_CR107","unstructured":"United States Food and Drug Administration. AVYCAZ safely and effectively. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf. Accessed 4 Mar 2021"},{"key":"4296_CR108","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE et al (2016) Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 62:1380\u20131389","journal-title":"Clin Infect Dis"},{"key":"4296_CR109","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM et al (2016) Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis 63:754\u2013762","journal-title":"Clin Infect Dis"},{"key":"4296_CR110","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A et al (2018) Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18:285\u2013295","journal-title":"Lancet Infect Dis"},{"key":"4296_CR111","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","volume":"60","author":"BLM de Jonge","year":"2016","unstructured":"de Jonge BLM et al (2016) In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 60:3163\u20133169","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR112","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dkz456","volume":"75","author":"I Spiliopoulou","year":"2020","unstructured":"Spiliopoulou I, Kazmierczak K, Stone GG (2020) In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u201317). J Antimicrob Chemother 75:384\u2013391","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR113","doi-asserted-by":"publisher","first-page":"e00989","DOI":"10.1128\/AAC.00989-17","volume":"61","author":"K Nelson","year":"2017","unstructured":"Nelson K et al (2017) Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrob Agents Chemother 61:e00989-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR114","first-page":"e00537","volume":"61","author":"RM Humphries","year":"2017","unstructured":"Humphries RM, Hemarajata P (2017) Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3. Antimicrob Agents Chemother 61:e00537-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR115","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","volume":"59","author":"RM Humphries","year":"2015","unstructured":"Humphries RM et al (2015) First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrob Agents Chemother 59:6605\u20136607","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR116","first-page":"e02097","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK et al (2017) Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother 61:e02097-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR117","first-page":"e00321","volume":"64","author":"L Poirel","year":"2020","unstructured":"Poirel L et al (2020) KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity. Antimicrob Agents Chemother 64:e00321-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR118","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1093\/jac\/dkv094","volume":"70","author":"ML Winkler","year":"2015","unstructured":"Winkler ML, Papp-Wallace KM, Bonomo RA (2015) Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop. J Antimicrob Chemother 70:2279\u20132286","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR119","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK et al (2016) Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis 63:1615\u20131618","journal-title":"Clin Infect Dis"},{"key":"4296_CR120","first-page":"e00389","volume":"61","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kashikar A, Brown CA, Denys G, Bush K (2017) Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam. Antimicrob Agents Chemother 61:e00389-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR121","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04197-3","author":"S Maraki","year":"2021","unstructured":"Maraki S et al (2021) Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. https:\/\/doi.org\/10.1007\/s10096-021-04197-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4296_CR122","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/cid\/ciz1159","volume":"71","author":"RK Shields","year":"2020","unstructured":"Shields RK, Doi Y (2020) Aztreonam Combination Therapy: An Answer to Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria? Clin Infect Dis 71:1099\u20131101","journal-title":"Clin Infect Dis"},{"key":"4296_CR123","doi-asserted-by":"publisher","first-page":"e00472","DOI":"10.1128\/AAC.00472-17","volume":"61","author":"JA Karlowsky","year":"2017","unstructured":"Karlowsky JA et al (2017) In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother 61:e00472-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR124","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","volume":"73","author":"E Shaw","year":"2018","unstructured":"Shaw E et al (2018) Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 73:1104\u20131106","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR125","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa586","author":"M Falcone","year":"2020","unstructured":"Falcone M et al (2020) Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa586","journal-title":"Clin Infect Dis"},{"key":"4296_CR126","doi-asserted-by":"publisher","first-page":"9684","DOI":"10.1038\/s41598-021-89255-8","volume":"11","author":"MF Alghoribi","year":"2021","unstructured":"Alghoribi MF et al (2021) Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam. Sci Rep 11:9684","journal-title":"Sci Rep"},{"key":"4296_CR127","unstructured":"Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580044. Accessed 28 May 2021"},{"key":"4296_CR128","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA et al (2020) Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother 75:618\u2013627","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR129","unstructured":"United States Food and Drug Administration. VABOMERE (meropenem and vaborbactam) for injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf. Accessed 12 Mar 2021"},{"key":"4296_CR130","unstructured":"European Medicines Agency (2018) Vaborem. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem. Accessed 12 Mar 2021"},{"key":"4296_CR131","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1060028018763288","volume":"52","author":"JC Cho","year":"2018","unstructured":"Cho JC, Zmarlicka MT, Shaeer KM, Pardo J (2018) Meropenem\/Vaborbactam, the First Carbapenem\/\u03b2-Lactamase Inhibitor Combination. Ann Pharmacother 52:769\u2013779","journal-title":"Ann Pharmacother"},{"key":"4296_CR132","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"SJ Hecker","year":"2015","unstructured":"Hecker SJ et al (2015) Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem 58:3682\u20133692","journal-title":"J Med Chem"},{"key":"4296_CR133","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O et al (2017) Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:e01443-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR134","first-page":"e00567","volume":"61","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK (2017) Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00567-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR135","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS et al (2018) Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 319:788\u2013799","journal-title":"JAMA"},{"key":"4296_CR136","first-page":"e01694","volume":"61","author":"D Sun","year":"2017","unstructured":"Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O (2017) Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61:e01694-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR137","doi-asserted-by":"publisher","unstructured":"Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y et al (2019) Effects of KPC Variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother 63. https:\/\/doi.org\/10.1128\/AAC.02048-18","DOI":"10.1128\/AAC.02048-18"},{"key":"4296_CR138","first-page":"e02208","volume":"64","author":"P Dulyayangkul","year":"2020","unstructured":"Dulyayangkul P, Wan Nur Ismah WAK, Douglas EJA, Avison MB (2020) Mutation of kvrA Causes OmpK35 and OmpK36 Porin Downregulation and Reduced Meropenem-Vaborbactam Susceptibility in KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 64:e02208-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR139","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s10096-015-2375-0","volume":"34","author":"I Olsen","year":"2015","unstructured":"Olsen I (2015) New promising \u03b2-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis 34:1303\u20131308","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4296_CR140","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG et al (2018) Imipenem-Relebactam and Meropenem\u2013Vaborbactam: Two Novel Carbapenem-\u00df-Lactamase Inhibitor Combinations. Drugs; Auckland 78:65\u201398","journal-title":"Drugs; Auckland"},{"key":"4296_CR141","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/IDR.S224228","volume":"13","author":"TA Campanella","year":"2020","unstructured":"Campanella TA, Gallagher JC (2020) A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date. Infect Drug Resist 13:4297\u20134308","journal-title":"Infect Drug Resist"},{"key":"4296_CR142","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1099\/jmm.0.001142","volume":"69","author":"SH Lob","year":"2020","unstructured":"Lob SH et al (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015\u20132017. J Med Microbiol 69:207\u2013217","journal-title":"J Med Microbiol"},{"key":"4296_CR143","unstructured":"United States Food and Drug Administration. RECARBRIO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212819s000lbl.pdf. Accessed 4 Mar 2021"},{"key":"4296_CR144","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/phar.2378","volume":"40","author":"JR Smith","year":"2020","unstructured":"Smith JR, Rybak JM, Claeys KC (2020) Imipenem-Cilastatin-Relebactam: A Novel \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Pharmacotherapy 40:343\u2013356","journal-title":"Pharmacotherapy"},{"key":"4296_CR145","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa803","author":"I Titov","year":"2020","unstructured":"Titov I et al (2020) A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa803","journal-title":"Clin Infect Dis"},{"key":"4296_CR146","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA (2016) Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations. Clin Infect Dis 63:234\u2013241","journal-title":"Clin Infect Dis"},{"key":"4296_CR147","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","volume":"13","author":"ES Armstrong","year":"2010","unstructured":"Armstrong ES, Miller GH (2010) Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol 13:565\u2013573","journal-title":"Curr Opin Microbiol"},{"key":"4296_CR148","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jac\/dkq408","volume":"66","author":"DM Livermore","year":"2011","unstructured":"Livermore DM et al (2011) Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48\u201353","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR149","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","volume":"79","author":"K Eljaaly","year":"2019","unstructured":"Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM (2019) Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs 79:243\u2013269","journal-title":"Drugs"},{"key":"4296_CR150","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1128\/AAC.02744-13","volume":"58","author":"A Walkty","year":"2014","unstructured":"Walkty A et al (2014) In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011\u20132012. Antimicrob Agents Chemother 58:2554\u20132563","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR151","unstructured":"United States Food and Drug Administration. Zemdri. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210303orig1s000lbl.pdf. Accessed 5 Mar 2021"},{"key":"4296_CR152","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner FME et al (2019) Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 380:729\u2013740","journal-title":"N Engl J Med"},{"key":"4296_CR153","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","volume":"380","author":"JA McKinnell","year":"2019","unstructured":"McKinnell JA et al (2019) Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med 380:791\u2013793","journal-title":"N Engl J Med"},{"key":"4296_CR154","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cmi.2018.07.020","volume":"24","author":"U Theuretzbacher","year":"2018","unstructured":"Theuretzbacher U, Paul M (2018) Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin. Clin Microbiol Infect 24:1231\u20131233","journal-title":"Clin Microbiol Infect"},{"key":"4296_CR155","unstructured":"Dimitrova EK (2020) Zemdri: Withdrawn application - European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/zemdri. Accessed 5 Mar 2021"},{"key":"4296_CR156","first-page":"411","volume":"18","author":"A Mullard","year":"2019","unstructured":"Mullard A (2019) Achaogen bankruptcy highlights antibacterial development woes. Nat Rev Drug Discov 18:411","journal-title":"Nat Rev Drug Discov"},{"key":"4296_CR157","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/phar.2203","volume":"39","author":"KM Shaeer","year":"2019","unstructured":"Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho J (2019) C. Plazomicin: A Next-Generation Aminoglycoside. Pharmacotherapy 39:77\u201393","journal-title":"Pharmacotherapy"},{"key":"4296_CR158","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1586\/eri.12.25","volume":"10","author":"GG Zhanel","year":"2012","unstructured":"Zhanel GG et al (2012) Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 10:459\u2013473","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4296_CR159","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jgar.2020.12.006","volume":"24","author":"M Roch","year":"2020","unstructured":"Roch M et al (2020) Vertical and horizontal dissemination of an IncC plasmid harbouring rmtB 16S rRNA methylase gene, conferring resistance to plazomicin, among invasive ST258 and ST16 KPC-producing Klebsiella pneumoniae. J Glob Antimicrob Resist 24:183\u2013189","journal-title":"J Glob Antimicrob Resist"},{"key":"4296_CR160","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/jm201465w","volume":"55","author":"X-Y Xiao","year":"2012","unstructured":"Xiao X-Y et al (2012) Fluorocyclines 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597\u2013605","journal-title":"J Med Chem"},{"key":"4296_CR161","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG et al (2016) Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs 76:567\u2013588","journal-title":"Drugs"},{"key":"4296_CR162","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ja.2016.73","volume":"69","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Lin X, Bush K (2016) In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot 69:600\u2013604","journal-title":"J Antibiot"},{"key":"4296_CR163","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N (2016) In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60:3840\u20133844","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR164","doi-asserted-by":"publisher","first-page":"106178","DOI":"10.1016\/j.ijantimicag.2020.106178","volume":"56","author":"JA Clark","year":"2020","unstructured":"Clark JA, Kulengowski B, Burgess DS (2020) In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae. Int. J Antimicrob Agents 56:106178","journal-title":"Int. J Antimicrob Agents"},{"key":"4296_CR165","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2217\/fmb-2019-0135","volume":"14","author":"JS Solomkin","year":"2019","unstructured":"Solomkin JS et al (2019) Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance. Future Microbiol 14:1293\u20131308","journal-title":"Future Microbiol"},{"key":"4296_CR166","unstructured":"United States Food and Drug Administration. XERAVA (eravacycline) for injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf. Accessed 8 Mar 2021"},{"key":"4296_CR167","unstructured":"European Medicines Agency. Xerava, INN-eravacycline. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xerava-epar-product-information_en.pdf. Accessed 8 Mar 2021"},{"key":"4296_CR168","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1128\/AAC.04967-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, O\u2019Brien W, Kerstein KO, Sutcliffe JA (2015) Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother 59:2446\u20132449","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR169","unstructured":"Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01978938. Accessed 8 Mar 2021"},{"key":"4296_CR170","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1060028019850173","volume":"53","author":"M Heaney","year":"2019","unstructured":"Heaney M, Mahoney MV, Gallagher JC (2019) Eravacycline: The Tetracyclines Strike Back. Ann Pharmacother 53:1124\u20131135","journal-title":"Ann Pharmacother"},{"key":"4296_CR171","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH et al (2012) Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559\u20132564","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR172","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nchembio.2376","volume":"13","author":"J Park","year":"2017","unstructured":"Park J et al (2017) Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes. Nat Chem Biol 13:730\u2013736","journal-title":"Nat Chem Biol"},{"key":"4296_CR173","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1093\/jac\/dkaa372","volume":"75","author":"Y Ding","year":"2020","unstructured":"Ding Y et al (2020) Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans. J Antimicrob Chemother 75:3480\u20133484","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR174","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1128\/AAC.01536-15","volume":"59","author":"L Honeyman","year":"2015","unstructured":"Honeyman L et al (2015) Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 59:7044\u20137053","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR175","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG et al (2020) Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs 80:285\u2013313","journal-title":"Drugs"},{"key":"4296_CR176","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W et al (2019) Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med 380:528\u2013538","journal-title":"N Engl J Med"},{"key":"4296_CR177","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R et al (2019) Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med 380:517\u2013527","journal-title":"N Engl J Med"},{"key":"4296_CR178","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W et al (2019) Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 19:1080\u20131090","journal-title":"Lancet Infect Dis"},{"key":"4296_CR179","unstructured":"United States Food and Drug Administration. NUZYRA (omadacycline). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. Accessed 8 Mar 2021"},{"key":"4296_CR180","unstructured":"Francisco EM (2019) Nuzyra: Withdrawn application - European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/nuzyra. Accessed 8 Mar 2021"},{"key":"4296_CR181","doi-asserted-by":"publisher","first-page":"e00499","DOI":"10.1128\/AAC.00499-20","volume":"64","author":"JD Lutgring","year":"2020","unstructured":"Lutgring JD et al (2020) Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018. Antimicrob. Agents Chemother 64:e00499-20","journal-title":"Antimicrob. Agents Chemother"},{"key":"4296_CR182","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10534-009-9219-2","volume":"22","author":"U M\u00f6llmann","year":"2009","unstructured":"M\u00f6llmann U, Heinisch L, Bauernfeind A, K\u00f6hler T, Ankel-Fuchs D (2009) Siderophores as drug delivery agents: application of the \u2018Trojan Horse\u2019 strategy. Biometals 22:615\u2013624","journal-title":"Biometals"},{"key":"4296_CR183","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1060028020929988","volume":"54","author":"RM El-Lababidi","year":"2020","unstructured":"El-Lababidi RM, Rizk JG (2020) Cefiderocol: A Siderophore Cephalosporin. Ann Pharmacother 54:1215\u20131231","journal-title":"Ann Pharmacother"},{"key":"4296_CR184","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.03098-15","volume":"60","author":"T Ito-Horiyama","year":"2016","unstructured":"Ito-Horiyama T et al (2016) Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother 60:4384\u20134386","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR185","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","volume":"52","author":"L Poirel","year":"2018","unstructured":"Poirel L, Kieffer N, Nordmann P (2018) Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int J Antimicrob Agents 52:866\u2013867","journal-title":"Int J Antimicrob Agents"},{"key":"4296_CR186","doi-asserted-by":"publisher","first-page":"S552","DOI":"10.1093\/cid\/ciz828","volume":"69","author":"T Katsube","year":"2019","unstructured":"Katsube T, Echols R, Wajima T (2019) Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin. Clin Infect Dis 69:S552\u2013S558","journal-title":"Clin Infect Dis"},{"key":"4296_CR187","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira N et al (2016) In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother 60:729\u2013734","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR188","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG et al (2019) Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79:271\u2013289","journal-title":"Drugs"},{"key":"4296_CR189","unstructured":"United States Food and Drug Administration. FETROJA (cefiderocol) for injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209445s002lbl.pdf. Accessed 8 Mar 2021"},{"key":"4296_CR190","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319\u20131328","journal-title":"Lancet Infect Dis"},{"key":"4296_CR191","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21:213\u2013225","journal-title":"Lancet Infect Dis"},{"key":"4296_CR192","unstructured":"Dimitrova EK (2020) Fetcroja. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja. Accessed 8 Mar 2021"},{"key":"4296_CR193","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226\u2013240","journal-title":"Lancet Infect Dis"},{"key":"4296_CR194","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1093\/cid\/ciz827","volume":"69","author":"Y Yamano","year":"2019","unstructured":"Yamano Y (2019) In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria. Clin Infect Dis 69:S544\u2013S551","journal-title":"Clin Infect Dis"},{"key":"4296_CR195","doi-asserted-by":"publisher","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","volume":"61","author":"MA Hackel","year":"2017","unstructured":"Hackel MA et al (2017) In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 61:e00093-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR196","first-page":"e01968","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel MA et al (2018) In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother 62:e01968-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR197","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","volume":"22","author":"N Kohira","year":"2020","unstructured":"Kohira N et al (2020) Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 22:738\u2013741","journal-title":"J Glob Antimicrob Resist"},{"key":"4296_CR198","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","volume":"25","author":"KE Kortright","year":"2019","unstructured":"Kortright KE, Chan BK, Koff JL, Turner PE (2019) Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe 25:219\u2013232","journal-title":"Cell Host Microbe"},{"key":"4296_CR199","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730\u2013733","journal-title":"Nat Med"},{"key":"4296_CR200","doi-asserted-by":"publisher","first-page":"e00066","DOI":"10.1128\/CMR.00066-18","volume":"32","author":"FL Gordillo Altamirano","year":"2019","unstructured":"Gordillo Altamirano FL, Barr JJ (2019) Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev 32:e00066-18","journal-title":"Clin Microbiol Rev"},{"key":"4296_CR201","doi-asserted-by":"publisher","first-page":"e2041","DOI":"10.1002\/rmv.2041","volume":"29","author":"S Rehman","year":"2019","unstructured":"Rehman S, Ali Z, Khan M, Bostan N, Naseem S (2019) The dawn of phage therapy. Rev Med Virol 29:e2041","journal-title":"Rev Med Virol"},{"key":"4296_CR202","doi-asserted-by":"crossref","unstructured":"Reindel R, Fiore CR (2017) Phage therapy: considerations and challenges for development.\u00a0Clin Infect Dis 64:1589\u20131590","DOI":"10.1093\/cid\/cix188"},{"key":"4296_CR203","doi-asserted-by":"publisher","first-page":"eaat9691","DOI":"10.1126\/science.aat9691","volume":"363","author":"JM Sweere","year":"2019","unstructured":"Sweere JM et al (2019) Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363:eaat9691","journal-title":"Science"},{"key":"4296_CR204","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","volume":"83","author":"N Chanishvili","year":"2012","unstructured":"Chanishvili N (2012) Phage therapy\u2013history from Twort and d\u2019Herelle through Soviet experience to current approaches. Adv Virus Res 83:3\u201340","journal-title":"Adv Virus Res"},{"key":"4296_CR205","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault P et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect Dis 19:35\u201345","journal-title":"Lancet Infect Dis"},{"key":"4296_CR206","doi-asserted-by":"publisher","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","volume":"7","author":"S Aslam","year":"2020","unstructured":"Aslam S et al (2020) Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States. Open Forum Infect Dis 7:ofaa389","journal-title":"Open Forum Infect Dis"},{"key":"4296_CR207","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3389\/fmicb.2017.01355","volume":"8","author":"L Amarillas","year":"2017","unstructured":"Amarillas L et al (2017) Isolation and Characterization of phiLLS, a Novel Phage with Potential Biocontrol Agent against Multidrug-Resistant Escherichia coli. Front Microbiol 8:1355","journal-title":"Front Microbiol"},{"key":"4296_CR208","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1007\/s00253-016-7858-0","volume":"100","author":"H Oliveira","year":"2016","unstructured":"Oliveira H et al (2016) Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. Appl Microbiol Biotechnol 100:10543\u201310553","journal-title":"Appl Microbiol Biotechnol"},{"key":"4296_CR209","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s00705-020-04822-0","volume":"165","author":"M Li","year":"2020","unstructured":"Li M et al (2020) Characterization and genome analysis of Klebsiella phage P509, with lytic activity against clinical carbapenem-resistant Klebsiella pneumoniae of the KL64 capsular type. Arch Virol 165:2799\u20132806","journal-title":"Arch Virol"},{"key":"4296_CR210","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3389\/fmicb.2020.01554","volume":"11","author":"M Li","year":"2020","unstructured":"Li M et al (2020) Isolation and Characterization of Novel Lytic Bacteriophages Infecting Epidemic Carbapenem-Resistant Klebsiella pneumoniae Strains. Front Microbiol 11:1554","journal-title":"Front Microbiol"},{"key":"4296_CR211","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1038\/s41598-020-62691-8","volume":"10","author":"M Horv\u00e1th","year":"2020","unstructured":"Horv\u00e1th M et al (2020) Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates. Sci Rep 10:5891","journal-title":"Sci Rep"},{"key":"4296_CR212","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/v10090482","volume":"10","author":"N Ciacci","year":"2018","unstructured":"Ciacci N et al (2018) Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101. Viruses 10:482","journal-title":"Viruses"},{"key":"4296_CR213","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jgar.2019.09.018","volume":"21","author":"T Anand","year":"2020","unstructured":"Anand T et al (2020) Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Glob Antimicrob Resist 21:34\u201341","journal-title":"J Glob Antimicrob Resist"},{"key":"4296_CR214","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317\u2013327","journal-title":"Nat Rev Microbiol"},{"key":"4296_CR215","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/antibiotics10020202","volume":"10","author":"D Guo","year":"2021","unstructured":"Guo D et al (2021) Genetic and Chemical Engineering of Phages for Controlling Multidrug-Resistant Bacteria. Antibiotics (Basel) 10:202","journal-title":"Antibiotics (Basel)"},{"key":"4296_CR216","unstructured":"World Health Organization (2017) Antibacterial Agents in Clinical Development: An analysis of the antibacterial clinical development pipeline, including tuberculosis. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/258965\/WHO-EMP-IAU-2017.11-eng.pdf?sequence=1"},{"key":"4296_CR217","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/jac\/dkw593","volume":"72","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N (2017) In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72:1373\u20131385","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR218","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/antibiotics8010032","volume":"8","author":"KS Thomson","year":"2019","unstructured":"Thomson KS, AbdelGhani S, Snyder JW, Thomson GK (2019) Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens. Antibiotics (Basel) 8:32","journal-title":"Antibiotics (Basel)"},{"key":"4296_CR219","first-page":"e00072","volume":"61","author":"HS Sader","year":"2017","unstructured":"Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK (2017) WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Antimicrob Agents Chemother 61:e00072-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR220","first-page":"e00682","volume":"62","author":"KA Rodvold","year":"2018","unstructured":"Rodvold KA et al (2018) Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects. Antimicrob Agents Chemother 62:e00682-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR221","first-page":"e01484","volume":"63","author":"RA Preston","year":"2019","unstructured":"Preston RA et al (2019) Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment. Antimicrob Agents Chemother 63:e01484-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR222","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu B et al (2020) Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-\u03b2-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem 63:2789\u20132801","journal-title":"J Med Chem"},{"key":"4296_CR223","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","volume":"62","author":"A Krajnc","year":"2019","unstructured":"Krajnc A et al (2019) Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-\u03b2-Lactamases. J Med Chem 62:8544\u20138556","journal-title":"J Med Chem"},{"key":"4296_CR224","doi-asserted-by":"publisher","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","volume":"64","author":"JC Hamrick","year":"2020","unstructured":"Hamrick JC et al (2020) VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-\u03b2-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR225","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1093\/jac\/dkaa373","volume":"75","author":"K Abdelraouf","year":"2020","unstructured":"Abdelraouf K, Almarzoky Abuhussain S, Nicolau DP (2020) In vivo pharmacodynamics of new-generation \u03b2-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-\u03b2-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 75:3601\u20133610","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR226","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bmcl.2018.01.006","volume":"28","author":"F Reck","year":"2018","unstructured":"Reck F et al (2018) Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. Bioorg Med Chem Lett 28:748\u2013755","journal-title":"Bioorg Med Chem Lett"},{"key":"4296_CR227","doi-asserted-by":"publisher","first-page":"e00552","DOI":"10.1128\/AAC.00552-18","volume":"62","author":"J Blais","year":"2018","unstructured":"Blais J et al (2018) In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 62:e00552-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR228","doi-asserted-by":"publisher","first-page":"e01200","DOI":"10.1128\/AAC.01200-18","volume":"62","author":"CR Dean","year":"2018","unstructured":"Dean CR et al (2018) Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother 62:e01200-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR229","doi-asserted-by":"publisher","first-page":"e02592","DOI":"10.1128\/AAC.02592-18","volume":"63","author":"M Osborn","year":"2019","unstructured":"Osborn M et al (2019) A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers. Antimicrob Agents Chemother 63:e02592-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR230","unstructured":"Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals. https:\/\/www.novartis.com\/news\/media-releases\/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals. Accessed 12 Mar 2021"},{"key":"4296_CR231","first-page":"e00432","volume":"63","author":"MD Barnes","year":"2019","unstructured":"Barnes MD et al (2019) Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrob Agents Chemother 63:e00432-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4296_CR232","doi-asserted-by":"publisher","first-page":"15802","DOI":"10.1021\/acs.jmedchem.0c01535","volume":"63","author":"DT Davies","year":"2020","unstructured":"Davies DT et al (2020) Discovery of ANT3310, a Novel Broad-Spectrum Serine \u03b2-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii. J Med Chem 63:15802\u201315820","journal-title":"J Med Chem"},{"key":"4296_CR233","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jac\/dky522","volume":"74","author":"S Mushtaq","year":"2019","unstructured":"Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM (2019) Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae. J Antimicrob Chemother 74:953\u2013960","journal-title":"J Antimicrob Chemother"},{"key":"4296_CR234","doi-asserted-by":"publisher","first-page":"e02229","DOI":"10.1128\/AAC.02229-19","volume":"64","author":"NL Mallalieu","year":"2020","unstructured":"Mallalieu NL et al (2020) Safety and Pharmacokinetic Characterization of Nacubactam, a Novel \u03b2-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers. Antimicrob Agents Chemother 64:e02229-19","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04296-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T11:11:41Z","timestamp":1631963501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":234,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4296"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04296-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}